MX2022011331A - Tratamiento secuencial de canceres utilizando 6-tio-dg, inhibidores de puntos de control y radioterapia. - Google Patents
Tratamiento secuencial de canceres utilizando 6-tio-dg, inhibidores de puntos de control y radioterapia.Info
- Publication number
- MX2022011331A MX2022011331A MX2022011331A MX2022011331A MX2022011331A MX 2022011331 A MX2022011331 A MX 2022011331A MX 2022011331 A MX2022011331 A MX 2022011331A MX 2022011331 A MX2022011331 A MX 2022011331A MX 2022011331 A MX2022011331 A MX 2022011331A
- Authority
- MX
- Mexico
- Prior art keywords
- thio
- radiation therapy
- checkpoint inhibitors
- cancers
- sequential treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989041P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022090 WO2021183873A1 (en) | 2020-03-13 | 2021-03-12 | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011331A true MX2022011331A (es) | 2022-10-27 |
Family
ID=77671975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011331A MX2022011331A (es) | 2020-03-13 | 2021-03-12 | Tratamiento secuencial de canceres utilizando 6-tio-dg, inhibidores de puntos de control y radioterapia. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12097213B2 (https=) |
| EP (1) | EP4117667B1 (https=) |
| JP (1) | JP7829491B2 (https=) |
| KR (1) | KR20220154134A (https=) |
| CN (1) | CN115397428A (https=) |
| AU (1) | AU2021233023B2 (https=) |
| BR (1) | BR112022018238A2 (https=) |
| CA (1) | CA3170930A1 (https=) |
| DK (1) | DK4117667T3 (https=) |
| ES (1) | ES3014683T3 (https=) |
| FI (1) | FI4117667T3 (https=) |
| HU (1) | HUE070513T2 (https=) |
| IL (1) | IL296403A (https=) |
| MX (1) | MX2022011331A (https=) |
| PL (1) | PL4117667T3 (https=) |
| PT (1) | PT4117667T (https=) |
| WO (1) | WO2021183873A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019183482A1 (en) | 2018-03-22 | 2019-09-26 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
| WO2025090539A1 (en) * | 2023-10-22 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012052181A1 (en) * | 2010-10-22 | 2012-04-26 | Roche Diagnostics Gmbh | A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide |
| CA2907924C (en) | 2013-04-08 | 2022-10-25 | The Board Of Regents Of The University Of Texas System | Telomerase mediated telomere altering compounds |
| CN116059219A (zh) * | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| US20180036331A1 (en) | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| EP3463370A4 (en) * | 2016-05-27 | 2020-04-08 | The Board of Regents of The University of Texas System | 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL |
| KR20190053909A (ko) | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | 항체와 체크포인트 면역 억제제의 병용 요법 |
| KR20240011262A (ko) * | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| JP2020515637A (ja) | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| US20210113602A1 (en) | 2018-02-28 | 2021-04-22 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA |
| WO2019183482A1 (en) * | 2018-03-22 | 2019-09-26 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
-
2021
- 2021-03-12 BR BR112022018238A patent/BR112022018238A2/pt unknown
- 2021-03-12 HU HUE21767125A patent/HUE070513T2/hu unknown
- 2021-03-12 JP JP2022554769A patent/JP7829491B2/ja active Active
- 2021-03-12 PL PL21767125.4T patent/PL4117667T3/pl unknown
- 2021-03-12 FI FIEP21767125.4T patent/FI4117667T3/fi active
- 2021-03-12 IL IL296403A patent/IL296403A/en unknown
- 2021-03-12 DK DK21767125.4T patent/DK4117667T3/da active
- 2021-03-12 MX MX2022011331A patent/MX2022011331A/es unknown
- 2021-03-12 PT PT217671254T patent/PT4117667T/pt unknown
- 2021-03-12 US US17/200,539 patent/US12097213B2/en active Active
- 2021-03-12 CN CN202180028952.2A patent/CN115397428A/zh active Pending
- 2021-03-12 AU AU2021233023A patent/AU2021233023B2/en active Active
- 2021-03-12 KR KR1020227033906A patent/KR20220154134A/ko active Pending
- 2021-03-12 CA CA3170930A patent/CA3170930A1/en active Pending
- 2021-03-12 EP EP21767125.4A patent/EP4117667B1/en active Active
- 2021-03-12 ES ES21767125T patent/ES3014683T3/es active Active
- 2021-03-12 WO PCT/US2021/022090 patent/WO2021183873A1/en not_active Ceased
-
2024
- 2024-09-09 US US18/829,162 patent/US20240424013A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12097213B2 (en) | 2024-09-24 |
| IL296403A (en) | 2022-11-01 |
| JP2023517671A (ja) | 2023-04-26 |
| EP4117667A4 (en) | 2023-11-15 |
| EP4117667A1 (en) | 2023-01-18 |
| AU2021233023B2 (en) | 2026-04-16 |
| DK4117667T3 (da) | 2025-02-10 |
| ES3014683T3 (en) | 2025-04-24 |
| BR112022018238A2 (pt) | 2022-10-25 |
| PL4117667T3 (pl) | 2025-04-07 |
| CA3170930A1 (en) | 2021-09-16 |
| CN115397428A (zh) | 2022-11-25 |
| AU2021233023A1 (en) | 2022-11-03 |
| EP4117667B1 (en) | 2024-12-18 |
| HUE070513T2 (hu) | 2025-06-28 |
| PT4117667T (pt) | 2025-02-06 |
| KR20220154134A (ko) | 2022-11-21 |
| FI4117667T3 (fi) | 2025-02-10 |
| US20210290652A1 (en) | 2021-09-23 |
| JP7829491B2 (ja) | 2026-03-13 |
| WO2021183873A1 (en) | 2021-09-16 |
| US20240424013A1 (en) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020817A2 (pt) | Inibidores de kif18a para tratamento de doenças neoplásicas | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2024012431A (es) | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| MX2016015346A (es) | Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| EP4368206A3 (en) | Dosing parameters for cd47 targeting therapies to hematologic malignancies | |
| MX2023006793A (es) | Tratamientos conjuntos para tratamiento de cancer her2. | |
| MX2022011331A (es) | Tratamiento secuencial de canceres utilizando 6-tio-dg, inhibidores de puntos de control y radioterapia. | |
| Jiang et al. | Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomes | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2022009091A (es) | Anticuerpos para usarse en terapia. | |
| EA201100626A1 (ru) | Лечение рака с помощью ионизирующего облучения и иммуноцитокинов | |
| MX2023006205A (es) | Tratamiento y diagnostico fotodinamico. | |
| MX2021010228A (es) | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. | |
| MX2025007373A (es) | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| WO2023102152A3 (en) | System, method, and computer readable medium for optimizing radiation treatment for a subject | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2020013883A (es) | Tratamientos oncológicos con agentes de zinc. | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer |